Who owns PRELUDE THERAPEUTICS INC?
- Ticker: PRLD
- CUSIP Number: 74065p101
Tip: Access positions for across all investors
Analyze quarterly positions in Prelude Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Prelude Therapeutics stock
Who bought or sold PRELUDE THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| OrbiMed Advisors | 11M | $16M | 0% | Sep 2025 |
|
| Baker Bros. Advisors | 10M | $15M | 0% | Sep 2025 |
|
| Millennium Management | 1.1M | $1.7M | 362% | Sep 2025 |
|
| Vanguard Group | 993k | $1.4M | 6% | Sep 2025 |
|
| Renaissance Technologies | 544k | $783k | -6% | Sep 2025 |
|
| Acadian Asset Management | 541k | $777k | 0% | Sep 2025 |
|
| Morgan Stanley | 284k | $230k | 100% | Jun 2025 |
|
| BlackRock | 265k | $382k | -39% | Sep 2025 |
|
| Two Sigma Advisers | 223k | $321k | -1% | Sep 2025 |
|
| Geode Capital Management | 218k | $313k | 0% | Sep 2025 |
|
| TD Asset Management | 161k | $231k | 0% | Sep 2025 |
|
| Two Sigma Investments | 152k | $219k | -2% | Sep 2025 |
|
| Shay Capital | 100k | $144k | 33% | Sep 2025 |
|
| State Street Corporation | 98k | $141k | 0% | Sep 2025 |
|
| Goldman Sachs Group | 79k | $114k | -49% | Sep 2025 |
|
| GSA Capital Partners | 75k | $108k | 5% | Sep 2025 |
|
| Manufacturers Life Insurance Company | 69k | $100k | 0% | Sep 2025 |
|
| Bridgeway Capital Management | 54k | $77k | -40% | Sep 2025 |
|
| Northern Trust | 36k | $52k | -4% | Sep 2025 |
|
| Jane Street | 35k | $50k | -62% | Sep 2025 |
|
| HPM Partners | 34k | $49k | -6% | Sep 2025 |
|
| Prudential Financial | 26k | $37k | 100% | Sep 2025 |
|
| Hrt Financial | 17k | $24k | 100% | Sep 2025 |
|
| XTX Topco | 16k | $22k | -63% | Sep 2025 |
|
| Hsbc Holdings | 14k | $20k | -21% | Sep 2025 |
|
| AQR Capital Management | 11k | $15k | -76% | Sep 2025 |
|
| FMR | 9.1k | $13k | -19% | Sep 2025 |
|
| Barclays | 8.7k | $13k | 1% | Sep 2025 |
|
| Royal Bank of Canada | 7.7k | $14k | 173% | Sep 2025 |
|
| Tower Research Capital | 6.9k | $10k | -59% | Sep 2025 |
|
| UBS Group | 4.2k | $6.0k | -96% | Sep 2025 |
|
| Jpmorgan Chase & Co | 3.9k | $5.6k | -84% | Sep 2025 |
|
| SBI Securities | 2.7k | $3.9k | 0% | Sep 2025 |
|
| NISA Investment Advisors | 1.6k | $2.4k | 0% | Sep 2025 |
|
| CWM | 1.2k | $2.0k | -70% | Sep 2025 |
|
| Pnc Financial Services | 1.2k | $1.7k | -1% | Sep 2025 |
|
| Group One Trading | 500.00 | $720.000000 | 0% | Sep 2025 |
|
| Simplex Trading | 153.00 | $0 | 100% | Sep 2025 |
|
| EverSource Wealth Advisors | 89.00 | $127.999800 | -40% | Sep 2025 |
|
| Bnp Paribas Arbitrage, Snc | 52.00 | $74.999600 | 0% | Sep 2025 |
|
| Optiver Holding B.V. | 20.00 | $29.000000 | 100% | Sep 2025 |
|
| IFP Advisors | 18.00 | $25.999200 | -47% | Sep 2025 |
|
| SRS Capital Advisors | 15.00 | $22.000500 | 100% | Sep 2025 |
|
Who sold out of Prelude Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Cantor Fitzgerald, L. P. | Jun 2025 | 212k | $172k |
| Charles Schwab Investment Management | Jun 2025 | 81k | $65k |
| Y-Intercept | Jun 2025 | 48k | $39k |
| Marshall Wace | Jun 2025 | 42k | $34k |
| Susquehanna International | Jun 2025 | 40k | $32k |
| Citadel Advisors | Jun 2025 | 34k | $27k |
| Wells Fargo & Company | Jun 2025 | 297.00 | $240.005700 |